References

[1] Foster RS, Beck S, Bihrle R. Secondary surgery in germ cell tumors—when and how extensively should it be performed? World J Urol 2004;22(1):37-40.

[2] Donohue JP, Foster RS. Retroperitoneal lymphade-nectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am 1998;25(3):461-8.

[3] Donohue JP, Roth LM, Zachary JM, et al. Cytore-ductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy. J Urol 1982;127(6):1111-4.

[4] Bracken RB, Johnson DE, Frazier OH, et al. The role of surgery following chemotherapy in stage III germ cell neoplasms. J Urol 1983;129(1):39-43.

[5] Freiha FS, Shortliffe LD, Rouse RV, et al. The extent of surgery after chemotherapy for advanced germ cell tumors. J Urol 1984;132(5):915-7.

[6] Pizzocaro G, Salvioni R, Pasi M, et al. Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage III and bulky stage II nonseminomatous testicular cancer. Cancer 1985;56(2):249-55.

[7] Fossa SD, Aass N, Ous S, et al. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol 1989;142(5):1239-42.

[8] Williams SN, Jenkins BJ, Baithun SI, et al. Radical retroperitoneal node dissection after chemotherapy for testicular tumours. Br J Urol 1989;63(6):641-3.

[9] Mulders PF, Oosterhof GO, Boetes C, et al. The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br J Urol 1990;66(4):425-9.

[10] Harding MJ, Brown IL, MacPherson SG, et al. Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol 1989;25(12): 1689-94.

[11] Aass N, Klepp O, Cavallin-Stahl E, et al. Prognostic factors in unselected patients with nonseminoma-tous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991;9(5):818-26.

[12] Kulkarni RP, Reynolds KW, Newlands ES, et al. Cytoreductive surgery in disseminated non-semi-nomatous germ cell tumours of testis. Br J Surg 1991;78(2):226-9.

[13] Brenner PC, Herr HW, Morse MJ, et al. Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol 1996;14(6): 1765-9.

[14] Stenning SP, Parkinson MC, Fisher C, et al. Post-chemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 1998;83(7):1409-19.

[15] Napier MP, Naraghi A, Christmas TJ, et al. Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours. Br J Cancer 2000;83(10):1274-80.

[16] Hendry WF, Norman AR, Dearnaley DP, et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 2002;94(6):1668-76.

[17] Muramaki M, Hara I, Miyake H, et al. Clinical outcome of retroperitoneal lymph node dissection after induction chemotherapy for metastatic non-semi-nomatous germ cell tumors. Int J Urol 2004;11(9): 763-7.

[18] Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratoma-tous germ cell tumor in postchemotherapy retroper-itoneal lymph node dissections. J Clin Oncol 1993; 11(7):1294-9.

[19] Logothetis CJ, Samuels ML, Trindade A, et al. The growing teratoma syndrome. Cancer 1982;50(8): 1629-35.

[20] Motzer RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998;159(1):133-8.

[21] Ahmed T, Bosl GJ, Hajdu SI. Teratoma with malignant transformation in germ cell tumors in men. Cancer 1985;56(4):860-3.

[22] Donadio AC, Motzer RJ, Bajorin DF, et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol 2003;21(23):4285-91.

[23] Baniel J, Foster RS, Rowland RG, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 1995;153(3 Pt 2): 976-80.

[24] Heidenreich A, Albers P, Hartmann M, et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonsemi-nomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 2003;169(5):1710-4.

[25] Foster RS, Donohue JP. Can retroperitoneal lym-phadenectomy be omitted in some patients after chemotherapy? Urol Clin North Am 1998;25(3):479-84.

[26] Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995;13(5):1177-87.

[27] Vergouwe Y, Steyerberg EW, de Wit R, et al. External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. Br J Cancer 2003;88(6):843-7.

[28] Matsuyama H, Yamamoto N, Sakatoku J, et al. Predictive factors for the histologic nature of residual tumor mass after chemotherapy in patients with advanced testicular cancer. Urology 1994;44(3):392-8 [discussion: 398-9].

[29] Onozawa M, Kawai K, Yamamoto T, et al. Clinical parameters that predict histology of postchemother-apy retroperitoneal lymph node mass in testicular cancer. Int J Urol 2004;11(7):535-41.

[30] Herr HW, Sheinfeld J, Puc HS, et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997;157(3):860-2.

[31] Ravi R, Ong J, Oliver RT, et al. The management of residual masses after chemotherapy in metastatic seminoma. BJU Int 1999;83(6):649-53.

[32] Flechon A, Bompas E, Biron P, et al. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002;168(5):1975-9.

[33] Donohue JP, Leviovitch I, Foster RS, et al. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol 1998; 16(2):65-71.

[34] Richie JP, Garnick MB, Finberg H. Computerized tomography: how accurate for abdominal staging of testis tumors? J Urol 1982;127(4):715-7.

[35] Debono DJ, Heilman DK, Einhorn LH, et al. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 1997;15(4):1455-64.

[36] Rabbani F, Goldenberg SL, Gleave ME, et al. Ret-roperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? Br J Urol 1998;81(2):295-300.

[37] Fossa SD, Qvist H, Stenwig AE, et al. Is postchemo-therapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992; 10(4):569-73.

[38] Stomper PC, Kalish LA, Garnick MB, et al. CT and pathologic predictive features ofresidual mass histo-logic findings after chemotherapy for nonseminoma-tous germ cell tumors: can residual malignancy or teratoma be excluded? Radiology 1991;180(3): 711-4.

[39] Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminoma-tous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990;8(10):1683-94.

[40] Oldenburg J, Alfsen GC, Lien HH, et al. Postchemo-therapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 2003;21(17):3310-7.

[41] Steyerberg EW, Marshall PB, Keizer HJ, et al. Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer: a decision analysis. Cancer 1999;85(6): 1331-41.

[42] Fossa SD, Ous S, Lien HH, et al. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicu-lar cancer. J Urol 1989;141(3):557-9.

[43] Carver BS, Bianco FJ Jr, Shayegan B, et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol 2006;176(1):100-4.

[44] Donohue JP, Rowland RG, Kopecky K, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 1987;137(6): 1176-9.

[45] Albers P, Weissbach L, Krege S, et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 2004;171(5):1835-8.

[46] Steyerberg EW, Gerl A, Fossa SD, et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 1998;16(1):269-74.

[47] De Wit M, Hartmann M, Brenner W, et al. [18F]-FDG-PET in germ cell tumors following chemotherapy: results of the German multicenter trial. J Clin Oncol. ASCO Annual Meeting Proceedings Part I 2006;24(Suppl 18):4521.

[48] Spermon JR, De Geus-Oei LF, Kiemeney LA, et al. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 2002;89(6):549-56.

[49] Sanchez D, Zudaire JJ, Fernandez JM, et al. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int 2002;89(9):912-6.

[50] Kollmannsberger C, Oechsle K, Dohmen BM, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 2002;94(9):2353-62.

[51] Stephens AW, Gonin R, Hutchins GD, et al. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996;14(5): 1637-41.

[52] De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22(6):1034-9.

[53] Johns Putra L, Lawrentschuk N, Ballok Z, et al. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology 2004;64(6):1202-7.

[54] Ganjoo KN, Chan RJ, Sharma M, et al. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 1999;17(11):3457-60.

[55] Beck SD, Foster RS, Bihrle R, et al. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 2005;23(25):6149-56.

[56] Albers P, Ganz A, Hannig E, et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 2000;164(2):381-4.

[57] International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15(2):594-603.

[58] Beck SD, Patel MI, Sheinfeld J. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors. J Urol 2004; 171(1):168-71.

[59] Wood DP Jr, Herr HW, Motzer RJ, et al. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer 1992; 70(9):2354-7.

[60] Eastham JA, Wilson TG, Russell C, et al. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 1994;43(1):74-80.

[61] Coogan CL, Foster RS, Rowland RG, et al. Post-chemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology 1997;50(6):957-62.

[62] Waples MJ, Messing EM. Redo retroperitoneal lym-phadenectomy for germ cell tumor. Urology 1993; 42(1):31-4.

[63] Donohue JP. Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprare-nal-hilar dissection. Urol Clin North Am 1977; 4(3):509-21.

[64] Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982;128(2):315-20.

[65] Donohue JP, Thornhill JA, Foster RS, et al. Retro-peritoneal lymphadenectomy for clinical stage A tes-tis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 1993;149(2): 237-43.

[66] Lange PH, Chang WY, Fraley EE. Fertility issues in the therapy of nonseminomatous testicular tumors. Urol Clin North Am 1987;14(4):731-47.

[67] Aprikian AG, Herr HW, Bajorin DF, et al. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 1994;74(4):1329-34.

[68] Sheinfeld J. Postchemotherapy retroperitoneal lymph node dissection and resection of residual masses for germ cell tumors of the testis. In: Vogelzang NJ, Scardino PT, Shipley WU, et al, editors. Comprehensive textbook of genitourinary oncology. 3rd edition. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 616-23.

[69] Weissbach L, Boedefeld EA. Localization of solitary and multiple metastases in stage II nonseminoma-tous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol 1987; 138(1):77-82.

[70] Foster RS. Modified retroperitoneal lymphadenec-tomy. BJU Int 2004;94(6):941-55.

[71] Nelson JB, Chen RN, Bishoff JT, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology 1999;54(6):1064-7.

[72] Janetschek G, Hobisch A, Peschel R, et al. Laparo-scopic retroperitoneal lymph node dissection. Urology 2000;55(1):136-40.

[73] Carver BS, Shayegan B, Motzer RJ, et al. The incidence and implications of disease outside a modified template in men undergoing post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic non-seminomatous germ cell tumors (NSGCT). J Urol 2006;175 (Suppl 4):192.

[74] Coogan CL, Hejase MJ, Wahle GR, et al. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 1996;156(5):1656-8.

[75] Nonomura N, Nishimura K, Takaha N, et al. Nerve-sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy. Int J Urol 2002;9(10):539-44.

[76] Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy-results from an international study group. J Clin Oncol 2001;19(10):2647-57.

[77] Karanikolas N, Serio A, Vickers A, et al. Viable germ cell tumor (GCT) identified at post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND): the significance of risk assignment and adjuvant chemotherapy. J Urol 2006;175(Suppl 4):191.

[78] NCCN Prostate Cancer Panel. NCCN guidelines on testicular cancer. Available at: http://www.nccn. org/professionals/physician_gls/PDF/testicular.pdf. Accessed June 13, 2006.

[79] Mosharafa AA, Foster RS, Koch MO, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 2004;171(5):1839-41.

[80] Gels ME, Nijboer AP, Hoekstra HJ, et al. Complications of the post-chemotherapy resection of retro-peritoneal residual tumour mass in patients with non-seminomatous testicular germ cell tumours. Br J Urol 1997;79(2):263-8.

[81] McKiernan JM,MotzerRJ,BajorinDF,etal. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology 2003;62(4):732-6.

[82] Heidenreich A, Ohlmann C, Hegele A, et al. Repeat retroperitoneal lymphadenectomy in advanced tes-ticular cancer. Eur Urol 2005;47(1):64-71.

[83] Tait D, Peckham MJ, Hendry WF, et al. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 1984;50(5):601-9.

[84] Gelderman WA, Schraffordt Koops H, Sleijfer DT, et al. Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin-vinblastine-bleomycin chemotherapy. J Surg Oncol 1988;38(4):227-32.

[85] Mandelbaum I, Yaw PB, Einhorn LH, et al. The importance of one-stage median sternotomy and retro-peritoneal node dissection in disseminated testicular cancer. Ann Thorac Surg 1983;36(5):524-8.

[86] Tiffany P, Morse MJ, Bosl G, et al. Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. Cancer 1986;57(5):978-83.

[87] Gerl A, Clemm C, Schmeller N, et al. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminoma-tous germ cell tumours. Br J Cancer 1994;70(5): 960-5.

[88] See WA, Laurenzo JF, Dreicer R, et al. Incidence and management of testicular carcinoma metastatic to the neck. J Urol 1996;155(2):590-2.

[89] Hartmann JT, Candelaria M, Kuczyk MA, et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 1997;33(6):843-7.

[90] Gels ME, Hoekstra HJ, Sleijfer DT, et al. Thora-cotomy for postchemotherapy resection of pulmonary residual tumor mass in patients with nonseminomatous testicular germ cell tumors: aggressive surgical resection is justified. Chest 1997; 112(4):967-73.

[91] Steyerberg EW, Keizer HJ, Messemer JE, et al. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT study group. Cancer 1997;79(2):345-55.

[92] Weisberger EC, McBride LC. Modified neck dissection for metastatic nonseminomatous testicular carcinoma. Laryngoscope 1999;109(8):1241-4.

[93] Hahn TL, Jacobson L, Einhorn LH, et al. Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol 1999;6(7):640-4.

[94] McGuire MS, Rabbani F, Mohseni H, et al. The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminom-atous germ cell tumours. BJU Int 2003;91(6): 469-73.

[95] Eskicorapci SY, Ekici S, Atsu MN, et al. Resection of pulmonary metastases following chemotherapy for high stage testicular tumors. Int J Urol 2004; 11(8):634-9.

Urol Clin N Am 34 (2007) 219-225

0 0

Post a comment